318 related articles for article (PubMed ID: 22573856)
1. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.
Sundar S; Singh A; Rai M; Prajapati VK; Singh AK; Ostyn B; Boelaert M; Dujardin JC; Chakravarty J
Clin Infect Dis; 2012 Aug; 55(4):543-50. PubMed ID: 22573856
[TBL] [Abstract][Full Text] [Related]
2. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
3. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
4. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
5. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
7. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Jha TK; Sundar S; Thakur CP; Bachmann P; Karbwang J; Fischer C; Voss A; Berman J
N Engl J Med; 1999 Dec; 341(24):1795-800. PubMed ID: 10588964
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
Bhattacharya SK; Jha TK; Sundar S; Thakur CP; Engel J; Sindermann H; Junge K; Karbwang J; Bryceson AD; Berman JD
Clin Infect Dis; 2004 Jan; 38(2):217-21. PubMed ID: 14699453
[TBL] [Abstract][Full Text] [Related]
10. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
[TBL] [Abstract][Full Text] [Related]
11. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
12. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.
Bhattacharya SK; Sinha PK; Sundar S; Thakur CP; Jha TK; Pandey K; Das VR; Kumar N; Lal C; Verma N; Singh VP; Ranjan A; Verma RB; Anders G; Sindermann H; Ganguly NK
J Infect Dis; 2007 Aug; 196(4):591-8. PubMed ID: 17624846
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India.
Pandey K; Ravidas V; Siddiqui NA; Sinha SK; Verma RB; Singh TP; Dhariwal AC; Das Gupta RK; Das P
Am J Trop Med Hyg; 2016 Nov; 95(5):1100-1105. PubMed ID: 27645786
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Katara GK; Verma S; Salotra P
Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
[TBL] [Abstract][Full Text] [Related]
15. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
16. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
[TBL] [Abstract][Full Text] [Related]
17. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
[TBL] [Abstract][Full Text] [Related]
18. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
[TBL] [Abstract][Full Text] [Related]
19. Trial of oral miltefosine for visceral leishmaniasis.
Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
[TBL] [Abstract][Full Text] [Related]
20. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]